

May 14, 2019  
Symbio Pharmaceuticals Limited  
(Securities Code: 4582)  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice Concerning Non-operating Expenses

Symbio Pharmaceuticals Limited (“the Company”) announces accrued non-operating expenses for the first quarter of the fiscal year ending December 31, 2019 (from January 1, 2019 to March 31, 2019).

### 1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 16,807 thousand yen under non-operating expenses for the first quarter of the fiscal year ending December 31, 2019 (from January 1, 2019 to March 31, 2019) due to recent fluctuations in foreign exchange rates.

### 2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating expense would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

### [Contact]

Investor Relations  
Tel: +81(0)3 5472 1125